Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Summary

For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.

Timeline

Start

2005-02

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped: “After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible.”

Drugs

Indications